Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers.

[1]  J. Ioannidis,et al.  Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. , 2003, American journal of obstetrics and gynecology.

[2]  T. Angtuaco,et al.  Prenatal diagnosis of congenital cardiac anomalies: a practical approach using two basic views. , 2002, Radiographics : a review publication of the Radiological Society of North America, Inc.

[3]  S. Cicero,et al.  Increased fetal nuchal translucency at 11–14 weeks , 2002, Prenatal diagnosis.

[4]  H. Orvos,et al.  Increased nuchal translucency and congenital heart defects in euploid fetuses. The Szeged experience. , 2002, European journal of obstetrics, gynecology, and reproductive biology.

[5]  B. Thilaganathan,et al.  Limitations of using first‐trimester nuchal translucency measurement in routine screening for major congenital heart defects , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[6]  G. Sharland,et al.  Nuchal translucency and congenital heart defects: heart failure or not? , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[7]  C. Bull,et al.  Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK , 1999, The Lancet.

[8]  Y. Ville,et al.  Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10–14 weeks of gestation as part of routine antenatal care in an unselected population , 1999, British journal of obstetrics and gynaecology.

[9]  K. Nicolaides,et al.  Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study , 1999, BMJ.

[10]  B. Mol.  Down's syndrome, cardiac anomalies, and nuchal translucency , 1999, BMJ.

[11]  C. Bull.  Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK. British Paediatric Cardiac Association. , 1999, Lancet.

[12]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[13]  A. Mcgregor,et al.  US Public Health Service sets out plan for xenotransplantation , 1998, The Lancet.

[14]  D. Mannino,et al.  Trends and patterns of mortality associated with birth defects and genetic diseases in the United States, 1979–1992: An analysis of multiple‐cause mortality data , 1997, Genetic epidemiology.

[15]  K. Nicolaides,et al.  Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation , 1996, British journal of obstetrics and gynaecology.

[16]  L. Allan,et al.  Echocardiographic detection of congenital heart disease in the fetus: present and future. , 1995, British heart journal.

[17]  K. Nicolaides,et al.  Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. , 1992, BMJ.